• metastatic, hormone-sensitive prostate cancer 11
• renal cell cancer (RCC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• avelumab based treatment
• avelumab plus axitinib
• nivolumab based treatment
• nivolumab alone
• nivolumab plus cabozantinib
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus axitinib
• pembrolizumab plus lenvatinib
• Immune checkpoint association
• nivolumab plus ipilimumab
• mTOR inhibitors
• everolimus
• lenvatinib plus everolimus
• VEGF(R) inhibitor
• lenvatinib
• lenvatinib in association

• versus all
• vs immune chekpoint inhibitors
• vs Immune checkpoint association
• vs nivolumab plus ipilimumab
• vs mTOR inhibitors
• vs everolimus
• vs non active control
• vs placebo
• vs VEGF(R) inhibitor
• vs sunitinib

  All patients Age < 65y (younger) Age > 75y (older) Gender, female Gender, male metastasis (bone) metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% previous nephrectomy (no) previous nephrectomy (yes) Risk intermediate (IMDC) Risk poor (IMDC)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

renal cell cancer (RCC), Immune checkpoint association vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;